With 9.7% CAGR, Sepsis Diagnostics Market Size to Reach USD 1,603.3 Million by 2030
17 avr. 2023 07h09 HE
|
Fortune Business Insights
Pune, India, April 17, 2023 (GLOBE NEWSWIRE) -- The global sepsis diagnostics market size was valued at USD 770.4 million in 2022. The market is projected to grow from USD 840.5 million in 2023 to...
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
29 mars 2023 08h30 HE
|
CytoSorbents
PRINCETON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
22 mars 2023 08h09 HE
|
CytoSorbents
PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Sepsis Diagnostics Market Size to Surpass USD 1582.23 Million by 2030 at 9.80% CAGR – Report by Market Research Future (MRFR)
02 févr. 2023 09h00 HE
|
Market Research Future
New York, USA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sepsis Diagnostics Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Sepsis Diagnostics Market...
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
26 janv. 2023 14h05 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases
06 janv. 2023 14h50 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
04 janv. 2023 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Global AI and Trust in Healthcare Research Report 2022: Validation of Models, Explainability and Transparency, & Data Ethics and AI
23 nov. 2022 06h38 HE
|
Research and Markets
Dublin, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The "2022 AI and Trust in Healthcare Report" report has been added to ResearchAndMarkets.com's offering. The"AI and Trust in Healthcare"report examines...
Sepsis Diagnostics Market Worth $1,226.52 Million, Globally, by 2028 at 9.2% CAGR - Exclusive Report by The Insight Partners
13 mai 2022 09h32 HE
|
The Insight Partners
New York, May 13, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product...
Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA
30 nov. 2021 11h40 HE
|
Biocartis NV
PRESS RELEASE: 30 November 2021, 17:40 CET SeptiCyte® RAPID Receives 510(k) clearance by US FDA Mechelen, Belgium, 30 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an...